Liontrust Investment Partners’s Beam Therapeutics BEAM Stock Holding History

Liontrust Investment Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Sell	60,025 -20,739	-26%	-$626K	0.03%	147
2026 Q1	$1.92M	Sell	80,764 -89,640	-53%	-$2.49M	0.03%	149
2025 Q4	$4.72M	Buy	+170,404	New	+$4.35M	0.07%	140
2025 Q2	–	Sell	-93,890	Closed	-$1.83M	–	199
2025 Q1	$1.83M	Sell	93,890 -16,290	-15%	-$427K	0.03%	152
2024 Q4	$2.73M	Buy	110,180 +30,180	+38%	+$770K	0.04%	136
2024 Q3	$1.87M	Hold	80,000	–	–	0.03%	151
2024 Q2	$1.87M	Buy	+80,000	New	+$1.96M	0.03%	151

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Liontrust Investment Partners's BEAM Position: Q2 2026 in Review

Liontrust Investment Partners reduced its Beam Therapeutics (BEAM) stake by 26% in Q2 2026, selling an estimated $626K and leaving 60,025 shares worth $2.06M. The position accounts for 0.03% of the portfolio, ranked #147.

Liontrust Investment Partners first reported a position in BEAM in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.72M in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Liontrust Investment Partners held 60,025 shares of Beam Therapeutics worth $2.06M as of Q2 2026.
Liontrust Investment Partners sold 20,739 Beam Therapeutics shares in Q2 2026, an estimated $626K.
Beam Therapeutics made up 0.03% of Liontrust Investment Partners's portfolio in Q2 2026, its #147 holding.
Liontrust Investment Partners first reported a position in Beam Therapeutics in Q2 2024 and has held it in 7 quarters since.
Liontrust Investment Partners's Beam Therapeutics position peaked at $4.72M in Q4 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Liontrust Investment Partners's 13F filing for Q2 2026, filed 18 Aug 2026.